AMARIN CORP PLC\UK (AMRN)
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - General
Amarin Corporation plc
Trials need funding. See this company's dilution risk and cash position.
- Phase 3Completed
Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day
Hypertriglyceridemia
NCT01047501Enrollment702StartDec 2009Primary CompletionFeb 2011CompletionFeb 2011 - Phase 3Completed
Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day
Hypertriglyceridemia
NCT01047683Enrollment229StartDec 2009Primary CompletionOct 2010CompletionJul 2011 - Phase 3Completed
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
AMR101, Placebo
Cardiovascular Diseases
NCT01492361Enrollment8,179StartNov 2011Primary CompletionMay 2018CompletionMay 2018
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 3 | Completed | AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day | NCT01047501 |
| Phase 3 | Completed | AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day | NCT01047683 |
| Phase 3 | Completed | AMR101, Placebo | NCT01492361 |